BRPI0517374A - formulação para tratamento ou prevenção de infecção respiratória, método para tratamento - Google Patents
formulação para tratamento ou prevenção de infecção respiratória, método para tratamentoInfo
- Publication number
- BRPI0517374A BRPI0517374A BRPI0517374-4A BRPI0517374A BRPI0517374A BR PI0517374 A BRPI0517374 A BR PI0517374A BR PI0517374 A BRPI0517374 A BR PI0517374A BR PI0517374 A BRPI0517374 A BR PI0517374A
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- treatment
- nanoparticles
- vaccine
- administered
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 8
- 206010057190 Respiratory tract infections Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 7
- 229940079593 drug Drugs 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- 239000002245 particle Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 239000011859 microparticle Substances 0.000 abstract 2
- 230000002685 pulmonary effect Effects 0.000 abstract 2
- 201000008827 tuberculosis Diseases 0.000 abstract 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 abstract 1
- 108010065839 Capreomycin Proteins 0.000 abstract 1
- 208000011738 Lichen planopilaris Diseases 0.000 abstract 1
- 206010027249 Meningitis meningococcal Diseases 0.000 abstract 1
- 201000010924 Meningococcal meningitis Diseases 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 241000700647 Variola virus Species 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 abstract 1
- 229960004602 capreomycin Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62373804P | 2004-10-29 | 2004-10-29 | |
| PCT/US2005/037484 WO2007011396A2 (en) | 2004-10-29 | 2005-10-19 | Particles for treatment of pulmonary infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0517374A true BRPI0517374A (pt) | 2008-10-07 |
Family
ID=37667331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517374-4A BRPI0517374A (pt) | 2004-10-29 | 2005-10-19 | formulação para tratamento ou prevenção de infecção respiratória, método para tratamento |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8846607B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1809252A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008518007A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101090711A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005334514B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0517374A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2585859C (cg-RX-API-DMAC7.html) |
| IL (1) | IL182785A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007119721A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007011396A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200703452B (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| EP3718566B1 (en) | 2008-12-09 | 2024-06-12 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
| RU2399385C1 (ru) * | 2009-03-10 | 2010-09-20 | Общество с ограниченной ответственностью "Научно-производственная фирма "НОРД" | Способ профилактической обработки животных и птиц |
| EP2421518A2 (en) * | 2009-04-24 | 2012-02-29 | Schering Corporation | Agglomerate formulations including active pharmaceutical agents with targeted particle sizes |
| NZ596610A (en) * | 2009-05-27 | 2014-04-30 | Samyang Biopharmaceuticals | A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same |
| CN102573886A (zh) * | 2009-09-17 | 2012-07-11 | 相互制药公司 | 用抗病毒剂治疗哮喘的方法 |
| CN102225058A (zh) * | 2011-06-22 | 2011-10-26 | 中国药科大学 | 磷酸奥司他韦吸入粉雾剂及其制备方法 |
| KR20140147891A (ko) * | 2012-04-13 | 2014-12-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 응집체 입자 |
| RU2562550C2 (ru) * | 2013-12-19 | 2015-09-10 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных" (ФГБНУ ВНИИБТЖ) | Способ специфической профилактики туберкулеза |
| KR102758377B1 (ko) | 2015-09-03 | 2025-01-23 | 노바백스, 인코포레이티드 | 개선된 안정성 및 면역원성을 갖는 백신 조성물 |
| WO2018226949A1 (en) | 2017-06-08 | 2018-12-13 | Pai Life Sciences Inc. | Cpzen compositions and uses |
| CN109260180A (zh) * | 2017-07-17 | 2019-01-25 | 北京盈科瑞创新药物研究有限公司 | 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法 |
| JP7317796B2 (ja) | 2017-07-24 | 2023-07-31 | ノババックス，インコーポレイテッド | 呼吸器疾患を治療するための方法および組成物 |
| IL305911B2 (en) | 2018-03-19 | 2025-01-01 | Novavax Inc | Multifunctional nanoparticle influenza vaccines |
| US20210338671A1 (en) * | 2018-07-24 | 2021-11-04 | Board Of Regents, The University Of Texas System | Compositions of surface-modified therapeutically active particles by ultra-rapid freezing |
| EP4142702A1 (en) * | 2020-05-01 | 2023-03-08 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
| US20230338365A1 (en) * | 2020-05-14 | 2023-10-26 | Kowa Company, Ltd. | Novel inhalant |
| JPWO2022044582A1 (cg-RX-API-DMAC7.html) * | 2020-08-28 | 2022-03-03 | ||
| CA3206024A1 (en) * | 2021-02-01 | 2022-08-04 | The Global Alliance For Tb Drug Development, Inc. | Pretomanid amorphous form |
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| CN113907360A (zh) * | 2021-07-30 | 2022-01-11 | 湖南达侑科技有限公司 | 植物甾醇磷脂组合物及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| WO1995022963A1 (en) * | 1994-02-28 | 1995-08-31 | Medinova Medical Consulting Gmbh | Drug targeting system, method for preparing same and its use |
| CZ295827B6 (cs) * | 1994-03-07 | 2005-11-16 | Nektar Therapeutics | Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití |
| US5814617A (en) * | 1994-10-07 | 1998-09-29 | The United States Of America As Represented By The Secretary Of The Navy | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene |
| ATE217792T1 (de) | 1995-07-05 | 2002-06-15 | Europ Economic Community | Biokompatibele und biodegradierbare nanokapseln zur absorption und verabreichung von proteinischen arzneimitteln |
| US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6517860B1 (en) * | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| DE60025019T2 (de) * | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
| US6766799B2 (en) * | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| JP2005511629A (ja) | 2001-11-20 | 2005-04-28 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 持続作用生成物送達用組成物 |
| GB0216562D0 (en) * | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
| WO2004024213A2 (en) * | 2002-09-12 | 2004-03-25 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Aerosolized capreomycin for inhibition of pulmonary tuberculosis |
| EP1556018A1 (en) * | 2002-09-30 | 2005-07-27 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| NZ541681A (en) | 2003-02-10 | 2009-02-28 | Bayer Healthcare Ag | Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts |
-
2005
- 2005-10-19 RU RU2007119721/15A patent/RU2007119721A/ru not_active Application Discontinuation
- 2005-10-19 JP JP2007538989A patent/JP2008518007A/ja active Pending
- 2005-10-19 EP EP05858453A patent/EP1809252A2/en not_active Withdrawn
- 2005-10-19 CA CA2585859A patent/CA2585859C/en not_active Expired - Fee Related
- 2005-10-19 US US11/720,595 patent/US8846607B2/en not_active Expired - Fee Related
- 2005-10-19 AU AU2005334514A patent/AU2005334514B2/en not_active Ceased
- 2005-10-19 BR BRPI0517374-4A patent/BRPI0517374A/pt not_active IP Right Cessation
- 2005-10-19 CN CNA2005800449753A patent/CN101090711A/zh active Pending
- 2005-10-19 WO PCT/US2005/037484 patent/WO2007011396A2/en not_active Ceased
-
2007
- 2007-04-25 IL IL182785A patent/IL182785A0/en unknown
- 2007-04-26 ZA ZA200703452A patent/ZA200703452B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2585859C (en) | 2012-03-06 |
| US20080213373A1 (en) | 2008-09-04 |
| EP1809252A2 (en) | 2007-07-25 |
| ZA200703452B (en) | 2008-06-25 |
| AU2005334514A1 (en) | 2007-01-25 |
| CN101090711A (zh) | 2007-12-19 |
| RU2007119721A (ru) | 2008-12-10 |
| US8846607B2 (en) | 2014-09-30 |
| IL182785A0 (en) | 2007-09-20 |
| CA2585859A1 (en) | 2007-01-25 |
| WO2007011396A3 (en) | 2007-05-03 |
| AU2005334514B2 (en) | 2009-11-26 |
| JP2008518007A (ja) | 2008-05-29 |
| WO2007011396A2 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517374A (pt) | formulação para tratamento ou prevenção de infecção respiratória, método para tratamento | |
| Pourshahab et al. | Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid | |
| Zarogoulidis et al. | Feasibility and effectiveness of inhaled carboplatin in NSCLC patients | |
| VanDevanter et al. | Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review | |
| BR9908771A (pt) | Processos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano, dispositivo para aumentar a biodisponibilidade de um agente ativo, e, dispositivos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano | |
| Adi et al. | Controlled release antibiotics for dry powder lung delivery | |
| ME02286B (me) | Jedinjenje za inhalaciju koje sadrži aklidinijum za lečenje hronične opstruktivne bolesti pluća | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| JP2013515022A (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| WO2005084638A3 (en) | Formulations decreasing infectivity of pulmonary diseases | |
| BR112014026957A8 (pt) | micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior | |
| JP2008518007A5 (cg-RX-API-DMAC7.html) | ||
| Yong et al. | Natural products-based inhaled formulations for treating pulmonary diseases | |
| US20230158259A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| JP2016535094A5 (cg-RX-API-DMAC7.html) | ||
| WO2013176622A1 (en) | A dry powder formulation | |
| Rossi et al. | Resistant tuberculosis: the latest advancements of second-line antibiotic inhalation products | |
| TW200815002A (en) | Treating cystic fibrosis with antibiotics via an aerosol drug | |
| Vazquez-Espinosa et al. | Tobramycin inhalation powder (TOBI Podhaler®) for the treatment of lung infection in patients with cystic fibrosis | |
| WO2015027848A1 (zh) | 含有帕拉米韦和/或其衍生物制剂的给药方法 | |
| US20160279057A1 (en) | Azelastine Formulations For Intranasal Nebulization And Irrigation | |
| Debnath et al. | Status of inhalable antimicrobial agents for lung infection: progress and prospects | |
| JP2011073987A (ja) | フコイダン用いた鼻喉吸入器、のどあめ、鼻腔用保湿剤。また流動層造粒加工したフコイダン。 | |
| Gunday Tureli et al. | Inhalable antibiotic nanoformulations for the treatment of pseudomonas aeruginosa infection in cystic fibrosis–a review | |
| CN108472375A (zh) | 中重度流感的治疗方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014. |